This trial is testing a combination of drugs to treat melanoma. The drugs are cabozantinib and pembrolizumab.
- Advanced Metastatic Melanoma
2 Primary · 3 Secondary · Reporting Duration: Initiation of treatment up to 2 years
Side Effects for
Awards & Highlights
1 Treatment Group
Cabozantinib and pembrolizumab
1 of 1
39 Total Participants · 1 Treatment Group
Primary Treatment: Cabozantinib · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the highest number of participants enrolled in this research?
"Affirmative, the clinical trial is presently accepting enrolment. The clinical trail was initially published on August 27th 2019 and its most recent update took place on August 19th 2022. 39 patients must be accepted at a single research institution to meet the requirements of this study." - Anonymous Online Contributor
Has Cabozantinib been previously investigated in any other research studies?
"Currently, 1062 medical trials are being conducted to investigate the efficacy of Cabozantinib. Of these studies, 133 have reached Phase 3 and feature 42531 clinical locations across Houston, Texas." - Anonymous Online Contributor
To what diseases is Cabozantinib typically administered?
"Cabozantinib, a common treatment for unresectable melanoma, has also been proven to alleviate symptoms of microsatellite instability high and reduce the risk of recurrence in certain diseases." - Anonymous Online Contributor
Are there any open slots available to join this investigation?
"The details on clinicaltrials.gov indicate that this trial is presently enrolled participants. This research project was inaugurated on August 27th 2019, and has recently been revised as of August 19th 2022." - Anonymous Online Contributor